Emerging drugs for the treatment of hemophilia A and B

References

• Poon MC, Luke KH. Haemophilia care in China: achievements of a decade of WFH treatment centre twinning activities. Haemophilia. 2008;14:879–888.
   PubMed Web of Science ®Google Scholar
• Horowitz B, Wiebe ME, Lippin A. Stryker MH inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl) phosphate detergent combinations. Transfusion. 1985;25:516–522.
   PubMed Web of Science ®Google Scholar
• Horowitz B, Wiebe ME, Lippin A, et al. Inactivation of viruses in labile blood derivatives. II. Physical methods. Transfusion. 1985;25:523–527.
   PubMed Web of Science ®Google Scholar
• Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428–2435.
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Brooker M, Amand RE, et al. A study of reported factor VIII use around the world. Haemophilia. 2010;6:33–46.
   Web of Science ®Google Scholar
• Alzoebie A, Belhani M, Eshghi P, et al. Establishing a harmonized haemophilia registry for countries with developing health care systems. Haemophilia. 2013;19:668–673.
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. Haemophilia. 2003;9:245–250.
   PubMed Web of Science ®Google Scholar
• Nijdam A, Kurnik K, Liesner R, et al. PedNet Study Group. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia. 2015;21:444–450.
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Berntorp E, Löfqvist T, et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25–32.
   PubMed Web of Science ®Google Scholar
• Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391–399.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, von Mackensen S, et al. ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700–710.
   PubMed Web of Science ®Google Scholar
• Soucie JM, De Staercke C, Monahan PE, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53:1217–1225.
   PubMed Web of Science ®Google Scholar
• Mohamed AF, Epstein JD, Li-McLeod JM. Patient and parent preferences for haemophilia A treatments. Haemophilia. 2011;17:209–214.
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Rocino A, et al. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. Haemophilia. 2014;20:128–135.
   PubMed Web of Science ®Google Scholar
• Morfini M, Coppola A, Franchini M, et al. Clinical use of factor VIII and factor IX concentrates. Blood Transfus. 2013;11(Suppl 4):55–63.
   PubMedGoogle Scholar
• Aronis S, Platokouki H, Kapsimali Z, et al. Prevalence of inhibitor formation in a cohort of haemophilic children exposed to several products of various purities. Haemophilia. 1995;1:236–242.
   PubMed Web of Science ®Google Scholar
• Blatny J, Komrska V, Blazek B, et al. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003. Blood Coagul Fibrinolysis. 2015;26:673–678.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood. 2012;119:4108–4114.
   PubMed Web of Science ®Google Scholar
• Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost. 2011;9:2180–2192.
   PubMed Web of Science ®Google Scholar
• Franchini M, Tagliaferri A, Mengoli C, et al. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol. 2012;81:82–93.
   PubMed Web of Science ®Google Scholar
• Xi M, Makris M, Marcucci M, et al. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost. 2013;11:1655–1662.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Blood. 2013;121:4046–4055.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231–239.
   PubMed Web of Science ®Google Scholar
• Farrugia A, O’Mahony B, Cassar J. Health technology assessment and haemophilia. Haemophilia. 2012;18:152–157.
   PubMed Web of Science ®Google Scholar
• Farrugia A, Noone D, Schlenkrich U, et al. Issues in assessing products for the treatment of hemophilia– the intersection between efficacy, economics, and ethics. J Blood Med. 2015;6:185–195.
   PubMed Web of Science ®Google Scholar
• Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia. 2013;19:660–667.
   PubMed Web of Science ®Google Scholar
• Warrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia. 1997;3:194–198.
   PubMed Web of Science ®Google Scholar
• Shah A, Delesen H, Garger S, et al. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia. 2015;21:766–771.
   PubMed Web of Science ®Google Scholar
• Kavakli K, Yang R, Rusen L, et al. LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13:360–369.
   PubMed Web of Science ®Google Scholar
• Ljung R, Kenet G, Mancuso ME, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD kids trial. Haemophilia. 2016;22:354–360.
   PubMed Web of Science ®Google Scholar
• Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16:349–359.
   PubMed Web of Science ®Google Scholar
• Ezban M, Vad K, Kjalke M. Turoctocog alfa (NovoEight®) – from design to clinical proof of concept. Eur J Haematol. 2014;93:369–376.
   PubMed Web of Science ®Google Scholar
• Haddley K. Turoctocog alfa for the treatment of hemophilia A. Drugs Today. 2014;50:121–131.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Bjerre J, Brand B, et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) – an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia. 2011;17:854–859.
   PubMed Web of Science ®Google Scholar
• Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19:691–697.
   PubMed Web of Science ®Google Scholar
• Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013;19:698–705.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Lentz SR, Misgav M, et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. Haemophilia. 2015;21:34–40.
   PubMed Web of Science ®Google Scholar
• Casademunt E, Martinelle K, Jernberg M, et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol. 2012;89:165–176.
   PubMed Web of Science ®Google Scholar
• Kannicht C, Ramström M, Kohla G, et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res. 2013;131:78–88.
   PubMed Web of Science ®Google Scholar
• Winge S, Yderland L, Kannicht C, et al. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line. Protein Expr Purif. 2015;115:165–175.
   PubMed Web of Science ®Google Scholar
• Sandberg H, Kannicht C, Stenlund P, et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res. 2012;130:808–817.
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Hampton K, von Depka M, et al. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety. Haemophilia. 2015 Aug 28. [Epub ahead of print]. doi:10.1111/hae.12793.
   Web of Science ®Google Scholar
• Klukowska A, Szczepański T, Vdovin V, et al. Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. Haemophilia. 2015 Sep 14. [Epub ahead of print]. doi:10.1111/hae.12797.
   Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031–3037.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317–325.
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13:967–977.
   PubMed Web of Science ®Google Scholar
• Nolan B, Mahlangu J, Perry D, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13:967–977.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Graninger M, et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie. 2012;32(Suppl. 1):S29–S38.
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126:1078–1085.
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in haemophilic mice models. Blood. 2013;121:2108–2116.
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fisher R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with haemophilia A. J Thromb Haemost. 2013;11:670–678.
   PubMed Web of Science ®Google Scholar
• Giangrande P, Chowdary P, Enhrenforth S, et al. Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocog alfa pegol, N8-GP): efficacy and safety in previously treated patients with severe hemophilia A – results of pathfinder™2 international trial. J Thromb Haemost. 2015;13:176.
   Web of Science ®Google Scholar
• Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116:270–279.
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014;12:488–496.
   PubMed Web of Science ®Google Scholar
• Boggio LN, Hong W, Wang M, et al. Bleeding phenotype with various Bay 94-9027 dosing regimens: sub-analyses from the protect VIII study [ Abstract]. Blood. 2014;124:1526.
   Google Scholar
• Schmidbauer S, Witzel R, Kreuter J, et al. Characterization of recombinant single chain FVIII, rVIII-single chain (CSL627). Haemophilia. 2012;18:37.
   PubMed Web of Science ®Google Scholar
• Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-Single Chain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134:125–131.
   PubMed Web of Science ®Google Scholar
• Zollner SB, Raquet E, Müller-Cohrs J, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res. 2013;132:280–287.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Lepatan LM, Vilchevska K, et al. rVIII-Single chain pharmacokinetics in adults, adolescents and children. J Thromb Haemost. 2015;13(Suppl. 2):603.
   Google Scholar
• Mahlangu J, Kuliczkowski K, Stasyshyn O, et al. rVIII-Single chain, results of the pivotal phase I/III PK,efficacy and safety clinical trial in adults and adolescents with severe hemophilia A. J Thromb Haemost. 2015;13(Suppl. 2):86.
   Google Scholar
• White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78:261–265.
   PubMed Web of Science ®Google Scholar
• Ewenstein BM, Joist JH, Shapiro AD, et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion. 2002;42:190–197.
   PubMed Web of Science ®Google Scholar
• Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001;7:133–139.
   PubMed Web of Science ®Google Scholar
• Miller GJ, Howarth DJ, Attfield JC, et al. Haemostatic factors in human peripheral afferent lymph. Thromb Haemost. 2000;83:427–432.
   PubMed Web of Science ®Google Scholar
• Stern DM, Drillings M, Nossel HL, et al. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA. 1983;80(13):4119–4123.
   PubMed Web of Science ®Google Scholar
• Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun. 1983;111:723–731.
   PubMed Web of Science ®Google Scholar
• Andreeva T, Zorenko VY, Davydkin I, et al. Safety and efficacy of new nonacog alfa drug (Innonafactor) in prophylactic treatment in patients with severe and moderate hemophilia B. Blood. 2015;126: Abstract n. 3532.
   Web of Science ®Google Scholar
• Morfini M, Dragani A, Paladino E, et al. Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. Haemophilia. 2016 Mar 14. [Epub ahead of print]. doi:10.1111/hae.12916.
   Google Scholar
• Scientific discussion for approval of Benefix at EMA. [cited 2000 Sep 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000139/WC500020390.pdf.
   Google Scholar
• Martinowitz U, Shapiro A, Quon DV, et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia. 2012;18:881–887.
   PubMed Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of pegylation on pharmaceuticals [ Review]. Nat Rev Drug Discov. 2003;2:214–21.
   PubMed Web of Science ®Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118:2695–2701.
   PubMed Web of Science ®Google Scholar
• Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124:3880–3886.
   PubMed Web of Science ®Google Scholar
• Negrier C, Young G, Abdul Karim F, et al. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia. 2016 Mar 3. [Epub ahead of print]. doi:10.1111/hae.12902.
   Google Scholar
• Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016;141:69–76.
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119:666–672.
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120:2405–2411.
   PubMed Web of Science ®Google Scholar
• Schulte S. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124(Suppl 2):S6–S8.
   PubMed Web of Science ®Google Scholar
• Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102:634–644.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127:1761–1769.
   PubMed Web of Science ®Google Scholar
• Powell JS, Apte S, Chambost H, et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015;168:124–134.
   PubMed Web of Science ®Google Scholar
• Diao L, Li S, Ludden T, et al. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet. 2014;53:467–477.
   PubMed Web of Science ®Google Scholar
• Monahan PE. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors. Hematology Am Soc Hematol Educ Program. 2015;2015:33–40.
   PubMedGoogle Scholar
• Waters EK, Genga RM, Schwartz MC, et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood. 2011;117:5514–5522.
   PubMed Web of Science ®Google Scholar
• Parunov LA, Fadeeva OA, Balandina AN, et al. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost. 2011;9:1825–1834.
   PubMed Web of Science ®Google Scholar
• Dockal M, Pachlinger R, Hartmann R, et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499. Blood. 2012;120:1104.
   Web of Science ®Google Scholar
• Bajaj MS, Birktoft JJ, Steer SA, et al. Structure and biology of tissue factor pathway inhibitor [ Review]. Thromb Haemost. 2001;86:959–72.
   PubMed Web of Science ®Google Scholar
• Petersen LC. Hemostatic properties of a TFPI antibody. Thromb Res. 2012;129(Suppl 2):S44–S45.
   PubMed Web of Science ®Google Scholar
• Hilden I, Lauritzen B, Sørensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119:5871–5878.
   PubMed Web of Science ®Google Scholar
• Hansen L, Petersen LC, Lauritzen B, et al. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of tissue factor pathway inhibitor. Thromb Res. 2014;133:464–471.
   PubMed Web of Science ®Google Scholar
• Agersø H, Overgaard RV, Petersen MB, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014;56:65–69.
   PubMed Web of Science ®Google Scholar
• Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13:743–754.
   PubMed Web of Science ®Google Scholar
• Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492–497.
   PubMed Web of Science ®Google Scholar
• Sampei Z1, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8:e57479.
   PubMed Web of Science ®Google Scholar
• Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124:3165–3171.
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633–1641.
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–2053.
   PubMed Web of Science ®Google Scholar
• Ruffo S, Messori A, Grasela TH, et al. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Programs Biomed. 1985;19:167–177.
   PubMedGoogle Scholar